• Nie Znaleziono Wyników

Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells

N/A
N/A
Protected

Academic year: 2022

Share "Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells"

Copied!
1
0
0

Pełen tekst

(1)

Synergistic anti-cancer activity of

the combination of dihydroartemisinin and doxorubicin in breast cancer cells

Guo-Sheng Wu

1

, Jin-Jian Lu

1,2

, Jia-Jie Guo

1

, Ming-Qing Huang

3

, Li Gan

2

, Xiu-Ping Chen

1

, Yi-Tao Wang

1

1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China

2College of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China

3College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, 350108, China Correspondence: Jin-Jian Lu, e-mail: jinjian.lu@163.com and Yi-Tao Wang, e-mail: ytwang@umac.mo

Abstract:

Background: Dihydroartemisinin (DHA) exhibits potent anti-malarial and anti-cancer activities. This study aimed to investigate the anti-proliferative effects of a combination of DHA and doxorubicin (DOX) on human breast cancer cells.

Methods: MTT assay and the combination index (CI) were used to show the anti-proliferative effects and calculate the synergism potential, respectively. Flow cytometry assay was used to detect apoptosis and the intracellular accumulation of DOX. JC-1 staining was used to determine the mitochondrial membrane potential. Western blot analysis was used to detect the protein expression of some apoptosis-related molecules.

Results: A synergistic anti-proliferative effect was found, and the enhanced anti-cancer activity was observed to be accompanied by the prompt onset of apoptosis in MCF-7 cells. The combinative treatment remarkably decreased the mitochondrial membrane poten- tial and activated caspase cascades more than the mono-treatment. Pretreatment with DHA also did not influence the accumulation of DOX in MCF-7 cells.

Conclusion: This study presented a new opportunity to enhance the effectiveness of future treatment regimens of breast cancer using DOX.

Key words:

dihydroartemisinin, doxorubicin, synergistic, anti-tumor, apoptosis; MCF-7

Pharmacological Reports, 2013, 65, 453–459 453

Pharmacological Reports 2013, 65, 453–459 ISSN 1734-1140

Copyright © 2013 by Institute of Pharmacology Polish Academy of Sciences

Cytaty

Powiązane dokumenty

Z przeprowadzonych badañ wy- nika, ¿e aktywnoœæ prokoagulanta nowotworowego (CP) mierzona cza- sem krzepniêcia w surowicy krwi chorych na raka sutka wynosi 144±17,0 s,

Bloch, Przyszła wojna pod względem technicznym, ekonomicznym i politycznym, PISM, Warsaw 2005, pp.. Portret zapomnianego pacyfisty

Яковлев А.А., Эволюция стратегий взаимодействия бизнеса и власти в российской экономике,

Pacuła P., Kryzys finansowy w Stanach Zjednoczonych i jego możliwe konsekwencje, Bez- pieczeństwo Narodowe

According to the narrow view, both citizens and officials should honour the re- quirements of public reason only while considering fundamental issues.. When discussing

A large prospective cohort study (n = 70 656) found that intake of folate was associated with a higher risk of breast can- cer [106] and that women who consumed ≥ 1,272 dietary

Final survival results of the ran- domized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer. Monk BJ, Herzog TJ,

Not cohesion or structural funds as suggested by most of the analysis performed during EU enlargements, but funds for preservation and manage- ment of natural resources, media,